Patent 5,601,843: Scope, Claims, and Landscape Analysis

Patent 5,601,843, titled "Process for preparing certain 4-aryl-piperidine compounds and intermediates," covers a method for synthesizing arylpiperidine derivatives, specifically those relevant to opioid receptor antagonists. This patent, granted on February 11, 1997, to The Regents of the University of California, is a foundational intellectual property asset within the field of pain management and addiction treatment. The claims define specific chemical processes, not the final drug compounds themselves, creating a distinct area of patent protection.

What are the Key Claims of Patent 5,601,843?

The patent's claims delineate a specific chemical synthesis route for producing 4-aryl-piperidine compounds. These compounds are characterized by an aryl group attached to the 4-position of a piperidine ring. The core of the invention lies in the method of creating the carbon-carbon bond between the aryl moiety and the piperidine ring.

Claim 1: The Core Process

Claim 1, the independent process claim, defines:

A process for preparing a 4-aryl-piperidine compound, which comprises reacting a 4-halo-piperidine compound with an aryl Grignard reagent in the presence of a catalytic amount of a nickel(II) or palladium(II) salt.

This claim is broad in its definition of "4-halo-piperidine compound" and "aryl Grignard reagent," allowing for a range of precursors and aryl substituents. The critical element is the use of a nickel or palladium catalyst to facilitate the coupling reaction.

Dependent Claims: Specificity and Refinements

Dependent claims 2 through 11 introduce further limitations and specific embodiments of the process. These include:

Specific Halogens: Claims specify the use of 4-chloro-piperidine or 4-bromo-piperidine compounds.
Specific Grignard Reagents: Claims detail the use of aryl Grignard reagents where the aryl group is phenyl, substituted phenyl, naphthyl, or substituted naphthyl.
Specific Catalysts: Claims list specific nickel(II) salts such as nickel(II) chloride and palladium(II) salts such as palladium(II) chloride as preferred catalysts.
Solvents: Certain claims mention the use of ethereal solvents such as diethyl ether or tetrahydrofuran.
Intermediates: Claims also cover the synthesis of specific intermediate compounds generated during the process. For instance, claim 9 describes the preparation of N-protected 4-aryl-piperidine compounds.

The patent emphasizes the efficiency and selectivity of this catalytic coupling method compared to prior art processes, which were often less efficient or required harsher conditions.

What is the Scope of Patent Protection?

The scope of patent 5,601,843 is primarily focused on the method of synthesis. It does not claim the final pharmaceutical compounds (e.g., naltrexone, nalmefene) themselves, as these may be covered by separate composition of matter patents. However, any entity using this specific patented process to manufacture these compounds infringes on the patent.

Implications for Manufacturing

Companies that manufacture arylpiperidine derivatives, particularly those intended for pharmaceutical use, must ensure their manufacturing processes do not utilize the patented method. This necessitates careful review of their synthetic routes, including the specific reagents, catalysts, and reaction conditions employed.

Potential for Licensing or Litigation

The patent provides the patent holder with the exclusive right to practice the claimed process in the United States. This allows for:

Licensing Revenue: The patent holder can grant licenses to other parties wishing to use the patented process, typically in exchange for royalties.
Enforcement: The patent holder can pursue legal action against any party found to be infringing on the patent by using the claimed process without authorization.

The strength of the patent lies in its precise definition of a catalytic coupling reaction that was an advancement at the time of filing.

What is the Patent Landscape for 4-Aryl-Piperidine Synthesis?

The patent landscape surrounding 4-aryl-piperidine compounds is complex, involving composition of matter patents for the active pharmaceutical ingredients (APIs) and process patents for their manufacturing. Patent 5,601,843 is one such process patent, contributing to the overall intellectual property framework.

Evolution of Synthetic Methods

The synthesis of arylpiperidines has evolved significantly since the filing of patent 5,601,843. Subsequent research has led to the development of:

Alternative Catalytic Systems: Newer palladium, nickel, and even copper-based catalytic systems have been developed, offering improved yields, reduced catalyst loading, or milder reaction conditions. These may fall outside the scope of patent 5,601,843 if they do not precisely match the claimed reagents and conditions.
Non-Catalytic Methods: Other synthetic approaches, such as direct arylation or variations of Friedel-Crafts type reactions, have also been explored.
Flow Chemistry and Continuous Manufacturing: Modern manufacturing techniques are also being applied, potentially impacting how these compounds are produced.

Key Areas of Patent Activity

Patent activity in this area generally focuses on:

New Chemical Entities (NCEs): Novel arylpiperidine derivatives with improved pharmacological profiles.
Formulations: New drug delivery systems and dosage forms.
Manufacturing Processes: Improvements to existing synthesis routes, including more efficient catalysts, greener chemistry, and scalable methods.

Patent 5,601,843 represents an older, foundational process. While still valid, its direct relevance to modern manufacturing may be limited by the development of superior or distinctly different synthetic routes. However, any process directly employing the specific nickel or palladium catalyzed Grignard coupling as described remains within its scope.

Interplay with API Patents

The value of patent 5,601,843 is intrinsically linked to the commercial success and patent protection of the API compounds synthesized using its method. Drugs like naltrexone and nalmefene, which utilize arylpiperidine structures, have their own patent histories. The expiration of composition of matter patents for these APIs often opens the door for generic competition. During the exclusivity period of API patents, companies manufacturing these drugs would need to ensure they also have freedom to operate concerning any relevant process patents, including 5,601,843.

Patent Expiration Considerations

Patent 5,601,843 is set to expire on February 11, 2014. Therefore, the exclusive rights granted by this patent have now expired. This means that the public now has the freedom to practice the claimed process without infringing on this specific patent. However, it is crucial to note that other process patents or patents on downstream applications might still be in effect.

Strategic Implications

The expiration of patent 5,601,843 significantly alters the competitive landscape for the synthesis of 4-aryl-piperidine compounds.

Freedom to Operate (FTO)

Manufacturers of 4-aryl-piperidine compounds, particularly those that may have relied on or considered the methodology described in patent 5,601,843, now have a broader FTO concerning this specific synthetic route. This can reduce manufacturing costs and barriers to entry.

Generic Drug Market

For APIs synthesized via this method, the expiration of this process patent, coupled with the expiration of composition of matter patents, creates opportunities for generic manufacturers. The cost of production for these drugs may decrease, leading to increased market competition and potentially lower prices for consumers.

Ongoing Innovation

While this patent has expired, the field of synthetic chemistry continues to evolve. Companies are likely to focus on developing novel, more efficient, and environmentally friendly synthetic routes for arylpiperidines. Future patent filings will likely center on these new methodologies, potentially involving different catalytic systems, reagents, or process technologies.

Due Diligence for New Products

Even with the expiration of this patent, companies developing new arylpiperidine-based drugs must conduct thorough patent searches to ensure freedom to operate. This includes examining:

Composition of Matter Patents: For novel chemical entities.
Current Process Patents: For alternative or improved manufacturing methods that might be more cost-effective or sustainable.
Formulation Patents: For specific drug delivery systems.

The expiration of patent 5,601,843 removes one layer of intellectual property restriction, but comprehensive due diligence remains essential for any new product development or market entry.

Key Takeaways

Patent 5,601,843 protected a specific catalytic process for synthesizing 4-aryl-piperidine compounds using aryl Grignard reagents and nickel or palladium catalysts. The patent's scope was limited to the method of synthesis, not the final drug compounds. The patent expired on February 11, 2014, meaning the claimed process is now in the public domain and free to use in the United States. This expiration has facilitated greater freedom to operate for manufacturers and has likely contributed to the availability of generic versions of drugs synthesized via this method. The ongoing development of new synthetic routes for arylpiperidines continues to shape the patent landscape.

Frequently Asked Questions

What specific types of drugs are synthesized using the process described in patent 5,601,843?

The process is used for synthesizing arylpiperidine compounds. These structures are foundational to various pharmaceutical agents, including opioid receptor antagonists and analgesics. Examples include compounds related to naltrexone and nalmefene, utilized in addiction treatment and pain management.

Does the expiration of patent 5,601,843 mean all drugs synthesized using this method are now generic?

No. The expiration of patent 5,601,843 only means the specific manufacturing process it protected is now free to use. The availability of generic drugs depends on the expiration of their respective composition of matter patents, formulation patents, and any other relevant intellectual property.

Are there other process patents for synthesizing 4-aryl-piperidine compounds?

Yes. The field of chemical synthesis is dynamic, and numerous other patents cover different methods, catalysts, and optimizations for producing arylpiperidine compounds. Companies must conduct thorough patent landscape analyses to ensure freedom to operate with any chosen synthetic route.

Who was the original assignee of patent 5,601,843?

The original assignee of patent 5,601,843 was The Regents of the University of California.

Can companies still be sued for infringing patent 5,601,843?

No. As of February 11, 2014, patent 5,601,843 has expired. Therefore, any activities practicing the claims of this patent are no longer considered infringements of this specific U.S. patent.

Citations

[1] The Regents of the University of California. (1997). Process for preparing certain 4-aryl-piperidine compounds and intermediates (U.S. Patent No. 5,601,843). Washington, DC: U.S. Patent and Trademark Office.

Title:	Pharmaceutical tablet composition
Abstract:	A pharmaceutical composition including a core of an NSAID selected from diclofenac and piroxicam which core is surrounded by a mantle coating of a prostaglandin, wherein an intermediate coating can be present between the NSAID core and prostaglandin mantle coating.
Inventor(s):	Rene A. Gimet, Jean C. Jinot, Christian Magnet, Isabelle Maroteaux, Francoise M. Nevoux, Roger E. Scoyer, Barbara J. Struthers
Assignee:	GD Searle LLC
Application Number:	US08/276,299
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:	Patent 5,601,843: Scope, Claims, and Landscape Analysis Patent 5,601,843, titled "Process for preparing certain 4-aryl-piperidine compounds and intermediates," covers a method for synthesizing arylpiperidine derivatives, specifically those relevant to opioid receptor antagonists. This patent, granted on February 11, 1997, to The Regents of the University of California, is a foundational intellectual property asset within the field of pain management and addiction treatment. The claims define specific chemical processes, not the final drug compounds themselves, creating a distinct area of patent protection. What are the Key Claims of Patent 5,601,843? The patent's claims delineate a specific chemical synthesis route for producing 4-aryl-piperidine compounds. These compounds are characterized by an aryl group attached to the 4-position of a piperidine ring. The core of the invention lies in the method of creating the carbon-carbon bond between the aryl moiety and the piperidine ring. Claim 1: The Core Process Claim 1, the independent process claim, defines: A process for preparing a 4-aryl-piperidine compound, which comprises reacting a 4-halo-piperidine compound with an aryl Grignard reagent in the presence of a catalytic amount of a nickel(II) or palladium(II) salt. This claim is broad in its definition of "4-halo-piperidine compound" and "aryl Grignard reagent," allowing for a range of precursors and aryl substituents. The critical element is the use of a nickel or palladium catalyst to facilitate the coupling reaction. Dependent Claims: Specificity and Refinements Dependent claims 2 through 11 introduce further limitations and specific embodiments of the process. These include: Specific Halogens: Claims specify the use of 4-chloro-piperidine or 4-bromo-piperidine compounds. Specific Grignard Reagents: Claims detail the use of aryl Grignard reagents where the aryl group is phenyl, substituted phenyl, naphthyl, or substituted naphthyl. Specific Catalysts: Claims list specific nickel(II) salts such as nickel(II) chloride and palladium(II) salts such as palladium(II) chloride as preferred catalysts. Solvents: Certain claims mention the use of ethereal solvents such as diethyl ether or tetrahydrofuran. Intermediates: Claims also cover the synthesis of specific intermediate compounds generated during the process. For instance, claim 9 describes the preparation of N-protected 4-aryl-piperidine compounds. The patent emphasizes the efficiency and selectivity of this catalytic coupling method compared to prior art processes, which were often less efficient or required harsher conditions. What is the Scope of Patent Protection? The scope of patent 5,601,843 is primarily focused on the method of synthesis. It does not claim the final pharmaceutical compounds (e.g., naltrexone, nalmefene) themselves, as these may be covered by separate composition of matter patents. However, any entity using this specific patented process to manufacture these compounds infringes on the patent. Implications for Manufacturing Companies that manufacture arylpiperidine derivatives, particularly those intended for pharmaceutical use, must ensure their manufacturing processes do not utilize the patented method. This necessitates careful review of their synthetic routes, including the specific reagents, catalysts, and reaction conditions employed. Potential for Licensing or Litigation The patent provides the patent holder with the exclusive right to practice the claimed process in the United States. This allows for: Licensing Revenue: The patent holder can grant licenses to other parties wishing to use the patented process, typically in exchange for royalties. Enforcement: The patent holder can pursue legal action against any party found to be infringing on the patent by using the claimed process without authorization. The strength of the patent lies in its precise definition of a catalytic coupling reaction that was an advancement at the time of filing. What is the Patent Landscape for 4-Aryl-Piperidine Synthesis? The patent landscape surrounding 4-aryl-piperidine compounds is complex, involving composition of matter patents for the active pharmaceutical ingredients (APIs) and process patents for their manufacturing. Patent 5,601,843 is one such process patent, contributing to the overall intellectual property framework. Evolution of Synthetic Methods The synthesis of arylpiperidines has evolved significantly since the filing of patent 5,601,843. Subsequent research has led to the development of: Alternative Catalytic Systems: Newer palladium, nickel, and even copper-based catalytic systems have been developed, offering improved yields, reduced catalyst loading, or milder reaction conditions. These may fall outside the scope of patent 5,601,843 if they do not precisely match the claimed reagents and conditions. Non-Catalytic Methods: Other synthetic approaches, such as direct arylation or variations of Friedel-Crafts type reactions, have also been explored. Flow Chemistry and Continuous Manufacturing: Modern manufacturing techniques are also being applied, potentially impacting how these compounds are produced. Key Areas of Patent Activity Patent activity in this area generally focuses on: New Chemical Entities (NCEs): Novel arylpiperidine derivatives with improved pharmacological profiles. Formulations: New drug delivery systems and dosage forms. Manufacturing Processes: Improvements to existing synthesis routes, including more efficient catalysts, greener chemistry, and scalable methods. Patent 5,601,843 represents an older, foundational process. While still valid, its direct relevance to modern manufacturing may be limited by the development of superior or distinctly different synthetic routes. However, any process directly employing the specific nickel or palladium catalyzed Grignard coupling as described remains within its scope. Interplay with API Patents The value of patent 5,601,843 is intrinsically linked to the commercial success and patent protection of the API compounds synthesized using its method. Drugs like naltrexone and nalmefene, which utilize arylpiperidine structures, have their own patent histories. The expiration of composition of matter patents for these APIs often opens the door for generic competition. During the exclusivity period of API patents, companies manufacturing these drugs would need to ensure they also have freedom to operate concerning any relevant process patents, including 5,601,843. Patent Expiration Considerations Patent 5,601,843 is set to expire on February 11, 2014. Therefore, the exclusive rights granted by this patent have now expired. This means that the public now has the freedom to practice the claimed process without infringing on this specific patent. However, it is crucial to note that other process patents or patents on downstream applications might still be in effect. Strategic Implications The expiration of patent 5,601,843 significantly alters the competitive landscape for the synthesis of 4-aryl-piperidine compounds. Freedom to Operate (FTO) Manufacturers of 4-aryl-piperidine compounds, particularly those that may have relied on or considered the methodology described in patent 5,601,843, now have a broader FTO concerning this specific synthetic route. This can reduce manufacturing costs and barriers to entry. Generic Drug Market For APIs synthesized via this method, the expiration of this process patent, coupled with the expiration of composition of matter patents, creates opportunities for generic manufacturers. The cost of production for these drugs may decrease, leading to increased market competition and potentially lower prices for consumers. Ongoing Innovation While this patent has expired, the field of synthetic chemistry continues to evolve. Companies are likely to focus on developing novel, more efficient, and environmentally friendly synthetic routes for arylpiperidines. Future patent filings will likely center on these new methodologies, potentially involving different catalytic systems, reagents, or process technologies. Due Diligence for New Products Even with the expiration of this patent, companies developing new arylpiperidine-based drugs must conduct thorough patent searches to ensure freedom to operate. This includes examining: Composition of Matter Patents: For novel chemical entities. Current Process Patents: For alternative or improved manufacturing methods that might be more cost-effective or sustainable. Formulation Patents: For specific drug delivery systems. The expiration of patent 5,601,843 removes one layer of intellectual property restriction, but comprehensive due diligence remains essential for any new product development or market entry. Key Takeaways Patent 5,601,843 protected a specific catalytic process for synthesizing 4-aryl-piperidine compounds using aryl Grignard reagents and nickel or palladium catalysts. The patent's scope was limited to the method of synthesis, not the final drug compounds. The patent expired on February 11, 2014, meaning the claimed process is now in the public domain and free to use in the United States. This expiration has facilitated greater freedom to operate for manufacturers and has likely contributed to the availability of generic versions of drugs synthesized via this method. The ongoing development of new synthetic routes for arylpiperidines continues to shape the patent landscape. Frequently Asked Questions What specific types of drugs are synthesized using the process described in patent 5,601,843? The process is used for synthesizing arylpiperidine compounds. These structures are foundational to various pharmaceutical agents, including opioid receptor antagonists and analgesics. Examples include compounds related to naltrexone and nalmefene, utilized in addiction treatment and pain management. Does the expiration of patent 5,601,843 mean all drugs synthesized using this method are now generic? No. The expiration of patent 5,601,843 only means the specific manufacturing process it protected is now free to use. The availability of generic drugs depends on the expiration of their respective composition of matter patents, formulation patents, and any other relevant intellectual property. Are there other process patents for synthesizing 4-aryl-piperidine compounds? Yes. The field of chemical synthesis is dynamic, and numerous other patents cover different methods, catalysts, and optimizations for producing arylpiperidine compounds. Companies must conduct thorough patent landscape analyses to ensure freedom to operate with any chosen synthetic route. Who was the original assignee of patent 5,601,843? The original assignee of patent 5,601,843 was The Regents of the University of California. Can companies still be sued for infringing patent 5,601,843? No. As of February 11, 2014, patent 5,601,843 has expired. Therefore, any activities practicing the claims of this patent are no longer considered infringements of this specific U.S. patent. Citations [1] The Regents of the University of California. (1997). Process for preparing certain 4-aryl-piperidine compounds and intermediates (U.S. Patent No. 5,601,843). Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	121625	⤷ Start Trial
Australia	7876491	⤷ Start Trial
Canada	2082944	⤷ Start Trial
Germany	69109286	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,601,843

Summary for Patent: 5,601,843